MARKET

SRPT

SRPT

Sarepta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

90.57
+0.03
+0.03%
After Hours: 90.57 0 0.00% 18:11 09/24 EDT
OPEN
90.10
PREV CLOSE
90.54
HIGH
91.80
LOW
90.01
VOLUME
968.41K
TURNOVER
--
52 WEEK HIGH
181.83
52 WEEK LOW
65.30
MARKET CAP
7.23B
P/E (TTM)
-11.2818
1D
5D
1M
3M
1Y
5Y
Selecta Biosciences Hires Kevin Tan as CFO
MT Newswires · 5d ago
Even after rising 6.4% this past week, Sarepta Therapeutics (NASDAQ:SRPT) shareholders are still down 44% over the past three years
Many investors define successful investing as beating the market average over the long term. But if you try your hand...
Simply Wall St. · 09/17 16:32
Arkansas cannot deny coverage for Sarepta's Duchenne drug -court
An Arkansas appeals court ruled that the state's Medicaid agency cannot deny coverage for an expensive drug manufactured by Sarepta Therapeutics Inc used to treat a rare muscle disorder in children, saying doing so violates federal law.
Reuters · 09/16 16:54
Guggenheim Upgrades Sarepta Therapeutics to Buy
Guggenheim analyst Whitney Ijem upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Neutral to Buy.
Benzinga · 09/15 11:31
Guggenheim Upgrades Sarepta Therapeutics to Buy from Neutral, Sets $100 Price Target
MT Newswires · 09/15 09:20
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
Zacks.com · 09/14 14:24
Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the World Muscle Society 2021 Virtual Congress (WMS 2021), taking place Sept. 20-24, ...
GlobeNewswire · 09/14 12:30
Sarepta Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual inv...
GlobeNewswire · 09/07 20:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRPT. Analyze the recent business situations of Sarepta through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRPT stock price target is 118.39 with a high estimate of 199.00 and a low estimate of 75.00.
EPS
Institutional Holdings
Institutions: 504
Institutional Holdings: 69.42M
% Owned: 86.94%
Shares Outstanding: 79.84M
TypeInstitutionsShares
Increased
101
7.35M
New
51
2.19M
Decreased
122
8.49M
Sold Out
84
2.63M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
M. Kathleen Behrens
President/Chief Executive Officer/Director
Douglas Ingram
Chief Financial Officer/Executive Vice President/Chief Accounting Officer
Ian Estepan
Executive Vice President/Chief Scientific Officer
Louise Rodino-Klapac
Executive Vice President
William Ciambrone
Executive Vice President
Gilmore O'Neill
Senior Vice President/General Counsel/Secretary
Ryan Brown
Independent Director
Richard Barry
Independent Director
Mary Gray
Independent Director
Claude Nicaise
Independent Director
Hans Wigzell
No Data
About SRPT
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Webull offers kinds of Sarepta Therapeutics Inc stock information, including NASDAQ:SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.